CONCEPT - Phase IV, Randomized, Prospective, Multicenter Comparison of Intermittent Schedule of Oxaliplatin Combined With FOLFOX/Bevacizumab vs Conventional Mode of Administration of FOLFOX [fluorouracil + folinic acid + oxaliplatin]/bevacizumab [Avastin] versus the Conventional Mode of Administration of FOLFOX/Bevacizumab + Neuroprophylaxis With Calcium/Magnesium for Optimization of First-Line Therapy of Metastatic Colorectal Cancer.

Trial Profile

CONCEPT - Phase IV, Randomized, Prospective, Multicenter Comparison of Intermittent Schedule of Oxaliplatin Combined With FOLFOX/Bevacizumab vs Conventional Mode of Administration of FOLFOX [fluorouracil + folinic acid + oxaliplatin]/bevacizumab [Avastin] versus the Conventional Mode of Administration of FOLFOX/Bevacizumab + Neuroprophylaxis With Calcium/Magnesium for Optimization of First-Line Therapy of Metastatic Colorectal Cancer.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2014

At a glance

  • Drugs Bevacizumab; Calcium gluconate; Fluorouracil; Folinic acid; Magnesium sulfate; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms CONCEPT
  • Most Recent Events

    • 07 Mar 2014 Results published in the Annals of Oncology.
    • 30 Jul 2007 Drug interaction leading to discontinuation reported in the Journal of Clinical Oncology.
    • 16 Jul 2007 Status changed from in progress to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top